MANKIND

What Mankind Pharma promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 20 tracked 3 delivered 4 missed 13 open
  • Long-term Employee Cost as % of Sales went quiet said Q4 FY26 Promised: what our endeavor is that the employee cost should be in the vicinity of 22% of the sales, plus/minus 0.5% here and there. Q1 FY27: No update provided on this long-term metric.
  • FY27 OTC Business Growth revised down said Q4 FY26 Promised: And hopefully, better growth, double-digit growth, I mean high teens growth would be there. Q1 FY27: Growth was very low due to a soft market and business model changes. Management revised guidance for Q2 onwards to 'high single-digit to double-digit', a step down from the original 'high teens' target.
  • EBITDA Margin delivered said Q4 FY25 Promised: EBITDA margins to be in the range of 25% to 26% in financial year '26 Q4 FY26: Achieved. Full year adjusted EBITDA margin came in at 25.4%, within the original guided range.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 20 tracked commitments for Mankind Pharma — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens